|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.610 AUD | +1.95% |
|
+2.76% | +2.76% |
| 31/12 | Integral Diagnostics Chair Buys Shares | MT |
| 18/12 | Goldman Sachs Starts Integral Diagnostics at Sell with AU$2.10 Price Target | MT |
| Capitalization | 97Cr 65Cr 56Cr 52Cr 49Cr 90Cr 5.9TCr 600.01Cr 236.59Cr 2.81TCr 243.74Cr 238.72Cr 10TCr | P/E ratio 2026 * |
21.8x | P/E ratio 2027 * | 17.4x |
|---|---|---|---|---|---|
| Enterprise value | 130Cr 87Cr 75Cr 70Cr 65Cr 120.83Cr 7.88TCr 801.82Cr 316.16Cr 3.76TCr 325.72Cr 319.01Cr 14TCr | EV / Sales 2026 * |
1.62x | EV / Sales 2027 * | 1.5x |
| Free-Float |
83.6% | Yield 2026 * |
3.21% | Yield 2027 * | 3.83% |
Last Transcript: Integral Diagnostics Limited
| 1 day | +1.95% | ||
| 1 week | +2.76% | ||
| Current month | +2.76% | ||
| 1 month | +5.24% | ||
| 6 months | -1.88% | ||
| Current year | +2.76% |
| 1 week | 2.52 |  | 2.71 |
| 1 month | 2.3 | | 2.71 |
| Current year | 2.48 | | 2.71 |
| 1 year | 1.91 | | 3.15 |
| 3 years | 1.64 | | 3.54 |
| 5 years | 1.64 | | 5.55 |
| 10 years | 1.04 | | 5.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Craig White
DFI | Director of Finance/CFO | - | 24/01/2022 |
Julian Gully
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2018 |
Nikki Valle
LAW | General Counsel | - | 14/12/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Raelene Murphy
BRD | Director/Board Member | 65 | 01/10/2017 |
Andrew Fay
BRD | Director/Board Member | 61 | 18/07/2022 |
Ingrid Player
BRD | Director/Board Member | 52 | 29/08/2023 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.95% | +2.76% | -11.82% | -20.43% | 65Cr | |
| -3.78% | -1.31% | +37.24% | +452.97% | 3.2TCr | |
| -0.13% | +3.79% | -16.34% | -25.67% | 767.76Cr | |
| -2.74% | -9.22% | +16.61% | +254.95% | 548.63Cr | |
| -1.10% | -20.17% | +58.34% | +599.82% | 312.4Cr | |
| -0.87% | -1.43% | -0.63% | +29.93% | 257.45Cr | |
| -12.86% | +16.34% | +136.39% | -5.64% | 221.62Cr | |
| -9.37% | -3.15% | +25.92% | -61.41% | 216.73Cr | |
| -0.61% | +2.50% | - | - | 180.66Cr | |
| -0.31% | -2.81% | -8.51% | +16.48% | 165.49Cr | |
| Average | -2.98% | -4.22% | +26.35% | +137.89% | 593.44Cr | |
| Weighted average by Cap. | -3.23% | -2.75% | +29.10% | +304.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 80Cr 54Cr 46Cr 43Cr 40Cr 75Cr 4.88TCr 496.39Cr 195.73Cr 2.33TCr 201.65Cr 197.5Cr 8.5TCr | 85Cr 57Cr 49Cr 46Cr 43Cr 79Cr 5.18TCr 526.55Cr 207.62Cr 2.47TCr 213.9Cr 209.49Cr 9.01TCr |
| Net income | 4.71Cr 3.15Cr 2.72Cr 2.53Cr 2.35Cr 4.38Cr 285.8Cr 29Cr 11Cr 136.33Cr 12Cr 12Cr 497.8Cr | 5.68Cr 3.8Cr 3.27Cr 3.05Cr 2.84Cr 5.28Cr 344.63Cr 35Cr 14Cr 164.39Cr 14Cr 14Cr 600.25Cr |
| Net Debt | 33Cr 22Cr 19Cr 18Cr 16Cr 30Cr 1.98TCr 201.81Cr 80Cr 946.13Cr 82Cr 80Cr 3.45TCr | 31Cr 21Cr 18Cr 17Cr 15Cr 29Cr 1.88TCr 191.05Cr 75Cr 895.66Cr 78Cr 76Cr 3.27TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/26/16 | 2.610 $ | +1.95% | 2,62,404 |
| 15/26/15 | 2.560 $ | -3.40% | 4,10,916 |
| 14/26/14 | 2.650 $ | +0.38% | 5,47,443 |
| 13/26/13 | 2.640 $ | +1.54% | 3,39,743 |
| 12/26/12 | 2.600 $ | +2.36% | 3,45,855 |
Delayed Quote Australian S.E., January 16, 2026 at 10:40 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IDX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition